Hantavirus: Structure, Replication, Transmission, and Immune Evasion

Hantaviruses are enveloped, negative-sense RNA viruses that circulate silently in rodent populations worldwide and occasionally spill over into humans, causing two severe diseases: hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus pulmonary syndrome (HPS, also called hantavirus cardiopulmonary syndrome) in the Americas. The virus family first drew wide public attention in 1993 when a mysterious respiratory illness killed several young, otherwise healthy people in the Four Corners region of the southwestern United States, an outbreak later traced to a novel pathogen called Sin Nombre virus carried by deer mice.¹ What makes hantaviruses particularly interesting to virologists is the combination of a segmented genome that enables genetic reassortment, an unusual cap-snatching strategy for making its messenger RNA, and a suite of immune-evasion tactics that let the virus replicate for days before the host mounts a defense.

Particle Architecture and Genome Layout

A hantavirus particle is roughly spherical to irregularly shaped, measuring about 120 to 160 nanometers across. It is wrapped in a lipid envelope stolen from the host cell, and that envelope is studded with spikes made of two glycoproteins called Gn and Gc.² Inside the envelope sit three segments of single-stranded RNA, each coated with many copies of the nucleocapsid (N) protein to form ribbon-like complexes called ribonucleoproteins. The three RNA segments are labeled by size: small (S), medium (M), and large (L). The S segment encodes the N protein, the M segment encodes the Gn and Gc glycoproteins as a single precursor that gets cleaved after translation, and the L segment encodes the RNA-dependent RNA polymerase (RdRp), the enzyme the virus uses to copy its genome and produce messenger RNA.³

High-resolution structural work has clarified how the glycoprotein coat is arranged. Each spike is built from four copies of a Gn-Gc pair, forming a (Gn/Gc)₄ unit. The Gn subunits hold each spike together through direct Gn-to-Gn contacts, while the broader lattice across the viral surface is stitched together by Gc-to-Gc contacts between neighboring spikes.⁴ This arrangement matters because it determines which parts of the surface are accessible to antibodies, a key consideration for vaccine and therapeutic design.

Getting Inside a Cell

Hantaviruses primarily target endothelial cells, the thin layer of cells lining blood vessels. For the New World hantaviruses that cause HPS, researchers have identified a specific host protein, protocadherin-1 (PCDH1), as a critical entry receptor. The glycoproteins on the virus surface directly bind the outermost domain of PCDH1 on pulmonary endothelial cells, allowing the virus to latch on and get internalized.⁵ Follow-up experiments showed that introducing just two point mutations into PCDH1 was enough to block hantavirus binding and protect against lethal infection, confirming that this interaction is a genuine receptor-virus handshake rather than a bystander effect.⁶

Integrins on the cell surface also play a role in hantavirus attachment, particularly beta-3 integrins for pathogenic strains. Once attached, the virus is thought to be taken into the cell by endocytosis. As the endosome acidifies, the Gc glycoprotein undergoes a conformational change that fuses the viral envelope with the endosomal membrane, releasing the ribonucleoprotein complexes into the cytoplasm where replication begins.

Cap Snatching and Transcription

Hantaviruses face a problem shared by all negative-sense RNA viruses: their genomic RNA cannot be directly read by the cell’s protein-making machinery. The virus must first transcribe its genome into messenger RNA (mRNA). But hantaviruses lack the ability to add a 5′ cap to their mRNAs on their own, and without a cap, the host cell’s ribosomes will not translate them. The solution is a strategy called cap snatching, in which the virus steals the capped ends of the host’s own mRNAs and uses them as primers to start transcription.

The process is remarkably choreographed. The N protein binds to the 5′ caps of host cell mRNAs and shields them from the cell’s normal degradation machinery. These rescued fragments are stored in structures called processing bodies (P bodies), cellular compartments normally involved in mRNA decay.⁷ The viral polymerase then cleaves these stored fragments into short capped primers, typically about 10 to 14 nucleotides long, ending in a guanosine residue. The polymerase preferentially targets nonsense mRNAs over those actively being translated and favors cleavage sites where the sequence near the cut point matches the 3′ end of the viral genomic RNA.⁸ The N protein’s endonuclease domain and a separate binding site for a host factor are both required for this process to work efficiently, meaning cap snatching depends on a partnership between viral and cellular components.

Genome Replication and the Prime-and-Realign Mechanism

Once the initial round of transcription produces viral mRNAs that are translated into new viral proteins, the polymerase switches from transcription mode to genome replication mode. During replication, the polymerase copies the full-length negative-sense genomic RNA into a positive-sense intermediate (the antigenome), and then copies that back into new negative-sense genomes destined for packaging into new virus particles.

Structural studies of the Hantaan virus polymerase captured in its active states show that replication initiation uses a “prime-and-realign” mechanism. Binding of the 5′ end of the viral RNA promoter triggers a large-scale reorganization of the polymerase, which recruits the 3′ end of the viral RNA into the active site. The 3′ end initially overshoots the active site by several positions, and the polymerase begins synthesizing a short stretch of RNA before realigning it to the correct starting position and continuing elongation.⁹ This mechanism ensures accurate copying of the genome ends, which carry the signals needed for packaging and for launching the next round of replication.

Assembly and Release

After the new viral proteins accumulate, the glycoproteins Gn and Gc are processed and transported to the Golgi apparatus, the cellular compartment where hantaviruses assemble. Live-cell imaging of Old World hantavirus glycoproteins has caught Gn and Gc interacting within the Golgi to form multimeric complexes of varying sizes, consistent with the spike lattice structure described above. These large glycoprotein clusters appear to be the initial assembly intermediates of the viral envelope.¹⁰ The ribonucleoprotein complexes, each carrying one genome segment along with a copy of the polymerase, are then packaged into the budding particles. Completed virions bud into the Golgi lumen and are eventually released from the cell through the secretory pathway. The entire process is slow compared to many other viruses; hantaviruses are not lytic, meaning they do not blow the cell open to get out, which has implications for how disease develops.

How Hantaviruses Spread

Hantaviruses circulate persistently in their rodent reservoir hosts, which shed virus in urine, droppings, and saliva. Humans typically become infected by inhaling aerosolized particles from contaminated rodent excreta, for example when sweeping out a dusty shed, cleaning a cabin that has been closed for the winter, or disturbing nesting material. Each hantavirus species tends to be associated with a specific rodent host: Sin Nombre virus with the deer mouse in North America, Hantaan virus with the striped field mouse in Asia, and Puumala virus with the bank vole in Europe.

Field research has revealed that the shedding dynamics in wild rodent populations are more complex than laboratory experiments initially suggested, with viral shedding patterns in natural settings sometimes deviating from the neat kinetics seen in captive animals.¹¹ This matters because it affects how we predict risk: spikes in human cases correlate not just with rodent population density but with the proportion of infected animals actively shedding virus.

Among all known hantaviruses, Andes virus stands out as the only one confirmed to spread from person to person. Full-length viral sequencing has been used to verify chains of human-to-human transmission, including a documented three-case cluster in Argentina in 2014.¹² The mechanism is thought to involve close contact during the early symptomatic phase. For all other hantaviruses, humans are dead-end hosts who do not pass the virus on.

How Disease Develops in Humans

The hallmark of severe hantavirus disease, whether it presents as HFRS or HPS, is a dramatic increase in vascular permeability. The virus infects endothelial cells lining capillaries and small blood vessels, but it does so without killing those cells outright. Instead, the infection alters the cells’ normal barrier function, causing fluid to leak from the bloodstream into surrounding tissues.¹³ In HPS, this fluid floods the lungs. In HFRS, it accumulates around the kidneys and can cause hemorrhagic complications.

Several molecular pathways contribute to this vascular leakage. Pathogenic hantaviruses enhance signaling through the VEGF receptor on endothelial cells, which drives the internalization of VE-cadherin, a protein that normally glues neighboring endothelial cells together. When VE-cadherin is pulled off the cell surface, the junctions between cells loosen and fluid seeps through.¹⁴ A separate pathway involves the activation of the plasma kallikrein-kinin system on the surface of infected cells, leading to increased production of bradykinin, a potent vasodilator that further boosts permeability. Blocking bradykinin or the enzymes that release it was enough to prevent the permeability changes in laboratory models.¹⁵ The Andes virus nucleocapsid protein itself can activate the RhoA signaling pathway in endothelial cells, and the drug fasudil, a RhoA-pathway inhibitor, reduced bradykinin-driven permeability in infected cells to control levels.¹⁶

Evading the Innate Immune Response

Hantaviruses are slow replicators, and their ability to establish infection depends heavily on delaying the host’s first line of defense: the interferon system. Type I interferons are signaling proteins that alert neighboring cells to a viral invasion and activate antiviral programs throughout the body. Hantaviruses deploy multiple proteins to suppress this alarm.

The glycoprotein precursor of New World hantaviruses is a potent interferon antagonist. Sin Nombre virus glycoprotein precursor alone can robustly block interferon-beta induction, while Andes virus uses a combination of its nucleocapsid protein and glycoprotein precursor to achieve the same suppression.¹⁷ More recently, Andes virus was found to encode a small nonstructural protein, NSs, that acts as an additional interferon antagonist. NSs works by suppressing signaling downstream of the cell’s virus-sensing machinery (the RIG-I and MDA5 pathways), specifically by interfering with the adaptor protein MAVS, which relays the danger signal from those sensors to the genes that turn on interferon production.¹⁸ Together, these mechanisms create a window early in infection during which the virus can replicate quietly without triggering a strong immune response.

The Immune Response and Its Double Edge

When the adaptive immune system finally catches up, the response is vigorous. In patients infected with Puumala virus, a surge of virus-specific cytotoxic T cells appears around the time symptoms begin, loaded with cell-killing molecules like granzyme B and perforin. About ten days after symptoms start, both the T-cell effector population and the viral load decline together, suggesting these T cells are central to clearing the infection.¹⁹

But the same immune response that clears the virus may also contribute to the worst symptoms. Researchers have proposed that hantavirus-specific T cells fuel the cytokine storm observed in severe HPS, contributing to the capillary leak that causes pulmonary edema and cardiogenic shock.¹⁹ The picture is complicated by animal model data: in Syrian golden hamsters fatally infected with Andes virus, T cells were abundant in the blood and lungs, yet depleting T cells made no difference to the outcome, suggesting they were neither protective nor harmful in that model.¹⁹ The mismatch between the hamster model and human disease observations is one of the open questions in hantavirus research and makes it difficult to design therapies that modulate the immune response without making things worse.

Reservoir Hosts Beyond Rodents

For decades, hantaviruses were considered exclusively rodent-borne, with the exception of one oddball virus found in shrews in India in 1964. That view changed dramatically starting around 2007. Since then, the majority of newly described hantavirus genotypes have come from shrews, moles, and even bats.²⁰ In China alone, researchers identified four novel hantaviruses from bats and shrews, including viruses in pipistrelle bats and horseshoe bats, species common across Asia.²¹

None of these shrew- or bat-borne hantaviruses have been linked to human disease so far. But their discovery reshaped the evolutionary story of the virus family. Rather than originating in rodents and occasionally jumping to other mammals, hantaviruses likely have a deep evolutionary history in multiple mammalian orders, with rodent-borne strains representing the lineages that happen to cause human illness. This broader host range also means surveillance programs focused only on rodents may miss circulating diversity that could matter in the future.

Genetic Reassortment and Viral Evolution

Because hantaviruses carry their genome on three separate RNA segments, co-infection of a single host cell with two different strains can produce reassortant viruses that carry a mix of segments from each parent. This is the same process that generates pandemic influenza strains, though on a smaller scale. Research on Tula virus in European common voles identified at least three distinct reassortment events between sister lineages of the virus. In one case, a reassortant strain carried M segments distinct from all other strains in its region while retaining S and L segments typical of local viruses, and a secondary reassortment event between that strain and a parental type generated yet another combination.²² That study connected reassortment opportunities to zones where different rodent subspecies overlapped and hybridized, suggesting that host ecology directly shapes viral evolution.

Ecological Connections to Human Outbreaks

Human hantavirus cases do not occur at a steady rate. In Europe, outbreaks of nephropathia epidemica (the mild HFRS caused by Puumala virus) follow a boom-and-bust pattern driven by an ecological chain reaction. Warm summers promote heavy seed production by beech and oak trees, known as mast years. The abundance of food fuels a population explosion among bank voles the following winter and spring. More voles mean more virus circulating, and more contact with humans.²³ Statistical analyses have shown that since 1993, every peak in European nephropathia epidemica cases was immediately preceded by a mast year. The correlation with hot summers two years before the outbreak and warmer autumns the year before reflects the climate conditions that drive seed production.²³ As climate patterns shift, these mast cycles may change in frequency and intensity, potentially altering the rhythm of hantavirus outbreaks in ways that are difficult to predict.

Diagnostics and the Challenge of Early Recognition

One practical problem with hantavirus infections is that early symptoms are nonspecific: fever, muscle aches, fatigue, and sometimes gastrointestinal complaints. These look like dozens of other illnesses, and without a high index of suspicion, the diagnosis is often missed on the first visit. Data from a European study of primary-care patients found that when doctors recognized hantavirus infection at the first visit, antibiotic use dropped dramatically compared to patients whose diagnosis was delayed (roughly 14% versus 53%), and hospitalization rates fell as well (about 30% versus 54%). Early clues included thrombocytopenia (low platelet counts), found in about two-thirds of patients, along with signs of kidney involvement such as blood or protein in the urine and elevated creatinine levels.²⁴ Serological testing for hantavirus-specific IgM antibodies remains the standard confirmatory test, but awareness of the clinical and epidemiological context, particularly rodent exposure history, is what gets the right test ordered in the first place.

Treatments and Vaccine Prospects

Despite decades of research, no broadly effective antiviral drug or globally licensed vaccine exists for hantavirus disease.²⁵ Inactivated whole-virus vaccines against Hantaan and Seoul viruses are licensed in South Korea and China, but their protective efficacy is uncertain, and the immune correlates of protection are not well defined.²⁶ DNA vaccines encoding the M segment glycoproteins of Hantaan and Puumala viruses have reached Phase 1 trials and showed some cross-neutralizing activity, though Hantaan DNA vaccine generated stronger cross-protection against related HFRS-causing viruses than the Puumala vaccine did.²⁷

On the therapeutic side, one of the more promising leads is monoclonal antibody therapy. A human antibody called SNV-42, isolated from a person who recovered from Sin Nombre virus infection, targets the Gn subunit of the glycoprotein spike. Structural analysis at near-atomic resolution showed that SNV-42 binds the membrane-distal tip of the virus surface and blocks both receptor recognition and the fusion step needed for cell entry. The antibody’s binding sequence closely matches germline-encoded gene segments, raising the possibility that most people’s immune systems could generate similar antibodies with the right vaccine stimulus.²⁸ For now, treatment of severe HPS remains largely supportive, centered on mechanical ventilation and sometimes extracorporeal membrane oxygenation (ECMO) in specialized centers, while HFRS management focuses on fluid balance and, in some regions, the antiviral ribavirin, though evidence for its benefit remains limited.

The gap between what researchers understand about hantavirus biology and what can actually be done in the clinic is wider than for most other viral hemorrhagic fevers. The virus’s slow replication, nonlytic life cycle, and reliance on host pathways like the bradykinin system and VEGF receptor signaling offer theoretical drug targets, but none has yet translated into an approved therapy. With climate change potentially reshaping rodent population dynamics and reassortment generating new viral lineages in the wild, closing that gap is a matter of growing urgency.